鼻洗在上呼吸道疾病患者中的疗效、安全性和耐受性。

IF 1.1 Q3 OTORHINOLARYNGOLOGY
International Archives of Otorhinolaryngology Pub Date : 2025-07-29 eCollection Date: 2025-07-01 DOI:10.1055/s-0045-1802576
Ignazio La Mantia, Giovanna Stilo, Lepanto Lentini, Giorgio Ciprandi
{"title":"鼻洗在上呼吸道疾病患者中的疗效、安全性和耐受性。","authors":"Ignazio La Mantia, Giovanna Stilo, Lepanto Lentini, Giorgio Ciprandi","doi":"10.1055/s-0045-1802576","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Nasal irrigation is a standard therapeutic option to clean the upper airways to remove abundant secretions and harmful substances. The Nasal Wash (SIIT, Milan, Italy) sinus irrigation system contains saline, bicarbonates, and polyethylene glycol.</p><p><strong>Objective: </strong>The present randomized controlled trial evaluated and compared the Nasal Wash hypertonic solution (NW-HS) with physiological saline (PS) in patients with nasal symptoms common to different upper airway diseases (infectious rhinitis, allergic rhinitis, and acute and chronic rhinosinusitis).</p><p><strong>Methods: </strong>The symptomatic patients were divided into two groups: those receiving NW-HS 1 to 2 times a day for 7 days and those receiving PS 1 to 2 times a day for 7 days. The primary efficacy measures included total nasal symptom score (TNSS) and the score on the verbal numeric rating scale (VNRS), assessed at baseline and during the treatment period.</p><p><strong>Results: </strong>In total, 70 patients participated in the trial: 35 were allocated to the NW-HS group and 35 to the PS group. In the NW-HS group, we observed a significant reduction in the TNSS over time, at rates higher than those of the PS group ( <i>p</i>  < 0.001), as well as a significant reduction in the VNRS score at all observation times, and also at rates higher than those of the PS group ( <i>p</i>  < 0.001). The safety was good for all patients.</p><p><strong>Conclusion: </strong>The present trial documented the efficacy and safety of NW-HS in the treatment of nasal symptoms common to upper respiratory tract disorders. Most of the beneficial effects appeared as early as three days after the beginning of the treatment. In addition, compared to PS, NW-HS showed impressive results; thus, it may represent a safe and valuable option in the non-pharmacological therapy for rhinitis.</p>","PeriodicalId":13731,"journal":{"name":"International Archives of Otorhinolaryngology","volume":"29 3","pages":"1-8"},"PeriodicalIF":1.1000,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12307079/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy, Safety, and Tolerability of Nasal Wash in Patients with Upper Respiratory Tract Diseases.\",\"authors\":\"Ignazio La Mantia, Giovanna Stilo, Lepanto Lentini, Giorgio Ciprandi\",\"doi\":\"10.1055/s-0045-1802576\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Nasal irrigation is a standard therapeutic option to clean the upper airways to remove abundant secretions and harmful substances. The Nasal Wash (SIIT, Milan, Italy) sinus irrigation system contains saline, bicarbonates, and polyethylene glycol.</p><p><strong>Objective: </strong>The present randomized controlled trial evaluated and compared the Nasal Wash hypertonic solution (NW-HS) with physiological saline (PS) in patients with nasal symptoms common to different upper airway diseases (infectious rhinitis, allergic rhinitis, and acute and chronic rhinosinusitis).</p><p><strong>Methods: </strong>The symptomatic patients were divided into two groups: those receiving NW-HS 1 to 2 times a day for 7 days and those receiving PS 1 to 2 times a day for 7 days. The primary efficacy measures included total nasal symptom score (TNSS) and the score on the verbal numeric rating scale (VNRS), assessed at baseline and during the treatment period.</p><p><strong>Results: </strong>In total, 70 patients participated in the trial: 35 were allocated to the NW-HS group and 35 to the PS group. In the NW-HS group, we observed a significant reduction in the TNSS over time, at rates higher than those of the PS group ( <i>p</i>  < 0.001), as well as a significant reduction in the VNRS score at all observation times, and also at rates higher than those of the PS group ( <i>p</i>  < 0.001). The safety was good for all patients.</p><p><strong>Conclusion: </strong>The present trial documented the efficacy and safety of NW-HS in the treatment of nasal symptoms common to upper respiratory tract disorders. Most of the beneficial effects appeared as early as three days after the beginning of the treatment. In addition, compared to PS, NW-HS showed impressive results; thus, it may represent a safe and valuable option in the non-pharmacological therapy for rhinitis.</p>\",\"PeriodicalId\":13731,\"journal\":{\"name\":\"International Archives of Otorhinolaryngology\",\"volume\":\"29 3\",\"pages\":\"1-8\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-07-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12307079/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Archives of Otorhinolaryngology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/s-0045-1802576\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Archives of Otorhinolaryngology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0045-1802576","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

鼻冲洗是一种标准的治疗选择,用于清洁上呼吸道,清除大量分泌物和有害物质。鼻洗(SIIT,米兰,意大利)鼻窦冲洗系统含有生理盐水,碳酸氢盐和聚乙二醇。目的:本随机对照试验对不同上呼吸道疾病(感染性鼻炎、变应性鼻炎、急慢性鼻窦炎)常见鼻部症状患者的鼻洗高渗液(NW-HS)与生理盐水(PS)进行评价和比较。方法:将有症状的患者分为两组:NW-HS组每日1 ~ 2次,连用7 d; PS组每日1 ~ 2次,连用7 d。主要疗效指标包括鼻症状总分(TNSS)和口头数字评定量表(VNRS)评分,分别在基线和治疗期间进行评估。结果:共70例患者参与试验,其中NW-HS组35例,PS组35例。在NW-HS组中,随着时间的推移,我们观察到TNSS的显著降低,其速率高于PS组(p结论:本试验证明了NW-HS治疗上呼吸道疾病常见的鼻症状的有效性和安全性。大多数有益效果早在治疗开始后三天就出现了。此外,与PS相比,NW-HS表现出令人印象深刻的效果;因此,在鼻炎的非药物治疗中,它可能是一种安全和有价值的选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Efficacy, Safety, and Tolerability of Nasal Wash in Patients with Upper Respiratory Tract Diseases.

Efficacy, Safety, and Tolerability of Nasal Wash in Patients with Upper Respiratory Tract Diseases.

Efficacy, Safety, and Tolerability of Nasal Wash in Patients with Upper Respiratory Tract Diseases.

Efficacy, Safety, and Tolerability of Nasal Wash in Patients with Upper Respiratory Tract Diseases.

Introduction: Nasal irrigation is a standard therapeutic option to clean the upper airways to remove abundant secretions and harmful substances. The Nasal Wash (SIIT, Milan, Italy) sinus irrigation system contains saline, bicarbonates, and polyethylene glycol.

Objective: The present randomized controlled trial evaluated and compared the Nasal Wash hypertonic solution (NW-HS) with physiological saline (PS) in patients with nasal symptoms common to different upper airway diseases (infectious rhinitis, allergic rhinitis, and acute and chronic rhinosinusitis).

Methods: The symptomatic patients were divided into two groups: those receiving NW-HS 1 to 2 times a day for 7 days and those receiving PS 1 to 2 times a day for 7 days. The primary efficacy measures included total nasal symptom score (TNSS) and the score on the verbal numeric rating scale (VNRS), assessed at baseline and during the treatment period.

Results: In total, 70 patients participated in the trial: 35 were allocated to the NW-HS group and 35 to the PS group. In the NW-HS group, we observed a significant reduction in the TNSS over time, at rates higher than those of the PS group ( p  < 0.001), as well as a significant reduction in the VNRS score at all observation times, and also at rates higher than those of the PS group ( p  < 0.001). The safety was good for all patients.

Conclusion: The present trial documented the efficacy and safety of NW-HS in the treatment of nasal symptoms common to upper respiratory tract disorders. Most of the beneficial effects appeared as early as three days after the beginning of the treatment. In addition, compared to PS, NW-HS showed impressive results; thus, it may represent a safe and valuable option in the non-pharmacological therapy for rhinitis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
84
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信